openPR Logo
Press release

Investigation announced for Investors in Revance Therapeutics, Inc. (NASDAQ: RVNC) over potential Wrongdoing

04-21-2022 12:53 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of current long term investors in Revance Therapeutics, Inc. (NASDAQ: RVNC) shares.

An investigation on behalf of current long term investors in Revance Therapeutics, Inc. (NASDAQ: RVNC) shares.

An investigation was announced for long-term investors in shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) concerning potential breaches of fiduciary duties by certain directors and officers of Revance Therapeutics, Inc.

Investors who are current long term investors in Revance Therapeutics, Inc. (NASDAQ: RVNC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: RVNC stocks follows a lawsuit filed against Revance Therapeutics, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: RVNC stocks, concerns whether certain Revance Therapeutics, Inc. directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges that, the Defendants made false and/or misleading statements and/or failed to disclose that quality control deficiencies existed at the Company's manufacturing facility for DAXI, that the foregoing deficiencies decreased the likelihood that the FDA would approve the DAXI BLA in its current form, that accordingly, it was unlikely that the DAXI BLA would obtain FDA approval within the timeframe the Company had represented to investors, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) have certain options and should contact the Shareholders Foundation.

Contact:
Christopher Clausen
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors in Revance Therapeutics, Inc. (NASDAQ: RVNC) over potential Wrongdoing here

News-ID: 2607608 • Views:

More Releases from Shareholders Foundation

Lawsuit for Investors in Sonder Holdings Inc. (NASDAQ: SOND) filed in effort to recover losses
Lawsuit for Investors in Sonder Holdings Inc. (NASDAQ: SOND) filed in effort to …
An investor, who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND), filed a lawsuit over alleged violations of Federal Securities Laws by Sonder Holdings Inc in connection with certain allegedly false and misleading statements. Investors who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: SOND investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com
Lawsuit filed for Investors in Ocugen, Inc. (NASDAQ: OCGN) in effort to recover losses
Lawsuit filed for Investors in Ocugen, Inc. (NASDAQ: OCGN) in effort to recover …
An investor, who purchased shares of Ocugen, Inc. (NASDAQ: OCGN), filed a lawsuit i over alleged violations of Federal Securities Laws by Ocugen, Inc.. Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: OCGN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. Malvern, PA based Ocugen, Inc., a
Investors who lost money with shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) should contact the Shareholders Foundation in connection with Lawsuit
Investors who lost money with shares of Evolv Technologies Holdings, Inc. (NASDA …
An investor, who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV), filed a lawsuit in the U.S. District Court for the District of Massachusetts over alleged violations of Federal Securities Laws by Evolv Technologies Holdings, Inc. f/k/a NewHold Investment Corp. Investors who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) have certain options and for certain investors are short and strict deadlines running. Deadline: May 24, 2024. NASDAQ: EVLV
Investigation announced for Investors who purchased shares of Comtech Telecommunications Corp. (NASDAQ: CMTL) over possible Violations of Securities Laws
Investigation announced for Investors who purchased shares of Comtech Telecommun …
Comtech Telecommunications Corp is under investigation over potential securities laws violations in connection with certain financial statements. Investors who purchased shares of Comtech Telecommunications Corp. (NASDAQ: CMTL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Comtech Telecommunications Corp. regarding its business, its prospects and its operations were materially false

All 5 Releases


More Releases for Revance

Deadline on Feb. 8th coming up in Lawsuit for INvestros in Revance Therapeutics, …
A deadline is coming up on February 8, 2022 in the lawsuit filed for certain investors of Revance Therapeutics, Inc. (NASDAQ: RVNC) over alleged securities laws violations by Revance Therapeutics, Inc. Investors who purchased shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) have certain options and there are strict and short deadlines running. Deadline: February 8, 2022. NASDAQ: RVNC stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -
Lawsuit filed for Investors in shares of Revance Therapeutics, Inc. (NASDAQ: RVN …
An investor in shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) filed a lawsuit over alleged Securities Laws violations by Revance Therapeutics, Inc. Investors who purchased shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) have certain options and for certain investors are short and strict deadlines running. Deadline: February 8, 2022. NASDAQ: RVNC investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. Newark, CA based Revance Therapeutics, Inc.,
Investigation for Investors in NASDAQ: RVNC shares over possible Wrongdoing at R …
Certain directors of Revance Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties. Investors who purchased shares of Revance Therapeutics, Inc. (NASDAQ: RVNC have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Revance Therapeutics, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders. Newark, CA based Revance Therapeutics,
Palmer Hyperhidrosis Treatment Market Research Report (2021-2027): Key Trends an …
Hyperhidrosis is a disorder that results in excessive sweating of palms, soles, or underarms. Palmer hyperhidrosis is excessive and uncontrollable hand sweating and is the most common type of hyperhidrosis. The sweating may range from mild to severe. Market Snapshot A recently published report by QY Research, titled “Global Palmer Hyperhidrosis Treatment Market Size, Status and Forecast 2022” gives an overview of the overall Palmer Hyperhidrosis Treatment market. This section
Investigation announced for Investors in shares of Revance Therapeutics, Inc. (N …
An investigation was announced over potential securities laws violations by Revance Therapeutics, Inc. in connection with certain financial statements. Investors who purchased shares of Revance Therapeutics, Inc. (NASDAQ: RVNC), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Revance Therapeutics, Inc. regarding its business, its prospects and its operations were
Cervical Dystonia Pipeline 2020-2022| Revance Therapeutics, Inc., Syneos Health, …
The Global Cervical Dystonia Pipeline Insights 2020-2022: The research study has been prepared with the use of in-depth qualitative and quantitative analyses of the global Cervical Dystonia Market. The report offers complete and intelligent analysis of the competition, segmentation, dynamics, and geographical advancement of the Global Cervical Dystonia Market. It takes into account the CAGR, value, volume, revenue, production, consumption, sales, Manufacturing cost, prices, and other key factors related to the